Evaxion Biotech A/SEVAX
13F holders, Q1 2026 (March 31)1holders
0new positions
0sold out
$3.72avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Evaxion Biotech A/S (EVAX) in their 13F filings, unchanged from Q4 2025. 0 opened new positions and 0 sold out. The largest holder was Merck & Co., Inc. ($4.5M).
- Company
- Evaxion Biotech A/S
- CUSIP
- 29970R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Merck & Co., Inc. | 1.29% | No change | 1,214,126 | $4.5M |
"% of holder's portfolio" is EVAX's weight in each manager's 13F, not the share of Evaxion Biotech A/S the manager owns.